Men who carry genetic variants linked to higher blood levels of tyrosine, an amino acid sold widely as a cognitive-performance supplement, lived roughly 0.91 fewer years on average than men without those variants, according to a study of approximately 270,000 UK Biobank participants published in the journal Aging. The finding, drawn from both observational and genetic analyses, did not appear in women, raising pointed questions about whether a supplement marketed for focus and mental clarity could carry a hidden cost for half the population.
Why the tyrosine-longevity link demands attention now
Tyrosine is a nonessential amino acid that the body uses to produce dopamine, norepinephrine, and adrenaline. Supplement brands pitch it as a way to sharpen focus under stress, and it appears in dozens of over-the-counter “brain boost” and pre-workout formulas. The new research does not test any specific product or dose. Instead, it uses a method called Mendelian randomization, which treats inherited genetic variants as natural experiments. Because these variants are assigned at conception, they approximate lifelong exposure to higher or lower tyrosine levels, free from the confounding that plagues ordinary diet studies.
The central tension is straightforward: men whose genetics pushed their circulating tyrosine higher showed a statistically significant reduction in lifespan, even after researchers adjusted for measured serum tyrosine itself. That gap between the genetic signal and the blood-level adjustment hints that the association may operate through biological pathways that go beyond the amino acid’s concentration in the bloodstream at any single point. If confirmed, the implication is that simply measuring someone’s tyrosine level in a clinic would not fully capture the risk.
Phenylalanine, a closely related amino acid that the body converts into tyrosine, showed weaker or null associations with mortality in the same dataset. The sex-specific split is also striking. Women carrying the same tyrosine-raising variants did not show shortened lifespans, a pattern the authors have not yet fully explained. Early coverage of the work on a science news site emphasized this male-only signal as one of the most unexpected outcomes.
How UK Biobank genetics and mortality data produced the 0.91-year estimate
The study, titled “The role of phenylalanine and tyrosine in longevity,” combined a traditional cohort analysis with Mendelian randomization. Researchers drew on metabolomic and genetic data from roughly 270,000 UK Biobank participants to estimate how genetically predicted amino-acid levels relate to all-cause mortality. The 0.91-year reduction in male lifespan carried a 95% confidence interval, meaning the statistical range around the estimate was narrow enough for the authors to treat it as a real signal rather than noise.
The genetic instruments themselves came from a large genome-wide association study that identified variants tied to serum amino acids, including both tyrosine and phenylalanine. Those variants served as the randomization tool: men who inherited more tyrosine-raising alleles were, in effect, sorted into a “higher exposure” group from birth. Separate UK Biobank metabolomics work has already shown that plasma amino-acid signatures can predict long-term mortality at scale among more than 260,000 participants, lending broader credibility to the idea that these blood markers carry real prognostic weight.
To estimate the impact on lifespan, the researchers translated hazard ratios derived from the genetic analysis into years of life lost, a common approach in population epidemiology. While any individual man’s risk will vary, the group-level estimate of 0.91 years lost offers a tangible way to think about the effect size. It is modest compared with heavy smoking or uncontrolled hypertension, but it is not trivial, especially for a single biochemical trait that many people attempt to manipulate with supplements.
A key caveat appears in the study’s own methods section. The authors state that circulating amino-acid levels respond to diet and supplements, but that genetic Mendelian randomization estimates reflect lifelong exposure and should not be treated as equivalent to a randomized controlled trial of supplementation. In plain terms, the study cannot say that taking a tyrosine capsule for six months will shorten a man’s life. What it can say is that a biological system tuned to produce more tyrosine over a lifetime is associated with dying sooner.
What the tyrosine findings cannot yet answer
Several gaps limit how far anyone can take these results. The UK Biobank did not collect individual-level records of supplement brand names, dosages, or duration of use. That means there is no direct line from a bottle of tyrosine pills to the mortality signal. The serum measurements capture total circulating tyrosine from all sources, including diet, endogenous production, and supplementation, without distinguishing among them.
The sex-specific mortality curves and confidence intervals are summarized only at the abstract level in the peer-reviewed paper. Full hazard ratios broken down by age band remain in the closed full text, making independent verification of the dose-response shape difficult for outside analysts. And because the UK Biobank cohort is overwhelmingly of European ancestry, the findings may not generalize to other populations with different dietary patterns or genetic architectures.
The hypothesis that genetic instruments predict mortality even after adjusting for measured serum tyrosine is consistent with the data as reported, but the biological mechanism remains open. Tyrosine feeds into catecholamine synthesis, melanin production, and thyroid hormone pathways. Which of those downstream effects, if any, drives the male-specific mortality association is a question the current study design cannot isolate. It is also unclear whether the risk is concentrated among men with particularly high genetically driven levels or whether it rises more gradually across the range of variation.
Other limitations are more practical. The follow-up period in UK Biobank, while substantial, still captures only a slice of participants’ lifespans, and cause-of-death data can be imprecise. Without a detailed breakdown of cardiovascular, neurodegenerative, and cancer outcomes, outside readers cannot yet tell which disease categories contribute most to the observed life-shortening effect. Nor can they see whether tyrosine interacts meaningfully with smoking, alcohol use, or other lifestyle factors that also shape longevity.
What this means for men taking tyrosine supplements
For men who currently take tyrosine supplements, the practical takeaway is limited but real: this genetic evidence suggests that a lifelong tendency toward higher tyrosine is linked to shorter survival, at least in one large European-ancestry cohort. That is not proof that short-term supplementation is harmful, but it cuts against the assumption that “more is better” for cognitive performance, particularly when benefits in healthy adults are modest and context-dependent in existing trials.
Men using tyrosine for occasional stress or focus might reasonably ask whether non-pharmacological strategies-sleep, exercise, structured breaks, or cognitive training-could meet the same goals without tinkering with amino-acid pathways. Those who take multi-ingredient pre-workout powders or nootropic stacks may not realize tyrosine is included; checking labels and considering lower-tyrosine alternatives is one low-cost response while the science matures.
Clinicians and dietitians, meanwhile, face a familiar balancing act. On one hand, the study’s design and scale make it more robust than small, short-term supplement trials. On the other, it remains an indirect line of evidence, and abruptly advising all male patients to avoid tyrosine outright would go beyond what the data clearly support. A more cautious, evidence-aligned stance is to flag the new findings for men who are heavy or long-term users and to emphasize that safety data for chronic high-dose use are sparse.
What researchers need to do next
The study’s authors and outside experts agree that replication is essential. Similar Mendelian randomization analyses in non-European cohorts could test whether the male-specific pattern holds across ancestries. Parallel work that links tyrosine-related genetic variants to specific causes of death might also clarify which biological systems are most affected.
Randomized controlled trials would not be able to mimic lifelong genetic exposure, but they could still probe shorter-term risks and benefits of supplementation in men and women separately. Trials that track blood pressure, heart rhythm, mood, and cognitive performance over months or years, at doses comparable to commercial products, would help fill in the current evidence gap. Until then, the new genetic signal stands as a cautionary note: even familiar amino acids, when pushed outside their usual range, may shape how long some of us live.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
